Critical Survey: Caladrius Biosciences (CLBS) versus Its Peers

Caladrius Biosciences (NASDAQ: CLBS) is one of 183 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Caladrius Biosciences to related businesses based on the strength of its institutional ownership, earnings, profitability, dividends, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

6.4% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Caladrius Biosciences and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caladrius Biosciences 0 0 1 0 3.00
Caladrius Biosciences Competitors 539 2443 6573 126 2.65

Caladrius Biosciences currently has a consensus target price of $7.00, indicating a potential upside of 109.58%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.91%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Caladrius Biosciences is more favorable than its peers.

Volatility and Risk

Caladrius Biosciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Caladrius Biosciences’ peers have a beta of 1.62, meaning that their average share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares Caladrius Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Caladrius Biosciences $35.28 million -$32.65 million 1.58
Caladrius Biosciences Competitors $217.29 million -$39.39 million -66.61

Caladrius Biosciences’ peers have higher revenue, but lower earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Caladrius Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caladrius Biosciences -84.10% -96.80% -43.98%
Caladrius Biosciences Competitors -4,654.02% -566.89% -40.75%


Caladrius Biosciences beats its peers on 7 of the 13 factors compared.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit